Hall W M, Ratliff T B
Cullman Medical Center, AL.
Ala Med. 1990 Oct;60(4):22, 24, 26-8.
This study reports the results of a retrospective review of the case records of 28 seriously ill patients who received intravenous cimetidine (generally 300 mg q8h) for the treatment of gastric discomfort and/or hemorrhage or for prophylaxis against stress-induced ulcers. Most of these patients presented with complex symptoms arising from a variety of pathological conditions including ischemic heart disease, myocardial infarction, cerebrovascular accident, pneumonia, and trauma. A number of patients also had acute gastrointestinal hemorrhage. Over two-thirds of the patients treated with intravenous cimetidine demonstrated a reduction in gastrointestinal symptom severity, and a statistically significant reduction in the mean severity rating for all patients was observed. Adverse reactions reported during cimetidine therapy were generally mild to moderate in severity and required discontinuance of therapy in only one patient. The most common complaint was headache. Intravenous cimetidine administered q8h offers a safe and cost-effective approach to H2-receptor blockade and reduction of gastric acid secretion in patients who are temporarily unable to take oral medication.
本研究报告了对28例重症患者病例记录的回顾性分析结果，这些患者接受静脉注射西咪替丁（一般为300毫克，每8小时一次）治疗胃部不适和/或出血，或预防应激性溃疡。这些患者大多因多种病理状况出现复杂症状，包括缺血性心脏病、心肌梗死、脑血管意外、肺炎和创伤。一些患者还出现急性胃肠道出血。超过三分之二接受静脉注射西咪替丁治疗的患者胃肠道症状严重程度有所降低，并且观察到所有患者的平均严重程度评分有统计学意义的降低。西咪替丁治疗期间报告的不良反应一般严重程度为轻至中度，仅1例患者需要停药。最常见的主诉是头痛。每8小时静脉注射一次西咪替丁为暂时无法口服药物的患者提供了一种安全且经济有效的H2受体阻断和减少胃酸分泌的方法。
